Gamida Cell Reports Second Quarter 2022 Financial Results and Provides Company Update

Gamida Cell Reports Second Quarter 2022 Financial Results and Provides Company Update




Gamida Cell Reports Second Quarter 2022 Financial Results and Provides Company Update

– Received FDA acceptance of BLA for omidubicel with Priority Review; PDUFA target action date set for January 30, 2023 –

– Dosed first patient in company-sponsored Phase 1/2 study of cryopreserved formulation of GDA-201 for the treatment of follicular and diffuse large B-cell lymphomas –

– Finished second quarter of 2022 with $55.1 million in cash;

sufficient funding for the company’s operations into mid-2023, excluding the cost of commercializing omidubicel –

Company to host conference call at 8:00 a.m. ET today –

BOSTON–(BUSINESS WIRE)–Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases, today provided a business update and reported financial results for the quarter ended June 30, 2022. Net loss for the second quarter of 2022 was $18.6 million, compared to a net loss of $23.6 million in the second quarter of 2021. As of June 30, 2022, Gamida Cell had total cash, cash equivalents and investments of $55.1 million.

Recently, Gamida Cell:

  • Received acceptance for filing from the U.S. Food and Drug Administration (FDA) with priority review for its Biologics License Application (BLA) for omidubicel. The BLA has been assigned a Prescription Drug User Fee Act (PDUFA) target action date of January 30, 2023. If approved, omidubicel will be the first allogeneic advanced stem cell therapy donor source for patients with blood cancers in need of a stem cell transplant.
  • Dosed the first patient in a company-sponsored Phase 1/2 study evaluating a cryopreserved formulation of GDA-201, a readily available cell therapy candidate for the treatment of follicular and diffuse large B-cell lymphomas.
  • Continued development of the company’s proprietary NAM-enabled NK cell pipeline, including genetically modified product candidates GDA-301, GDA-401, GDA-501 and GDA-601, which aim to treat solid-tumor and hematological cancers. These cell therapy candidates utilize CAR, membrane bound- and CRISPR-mediated technologies to increase the NK cell targeting, potency and persistence against hematologic malignancies and solid tumors. Promising new pre-clinical data on GDA-301 and GDA-601 were presented at the International Society for Cell & Gene Therapy Meeting. The data demonstrated that both NAM-enabled cell therapy candidates represented a novel potent and cytotoxic approach in fighting cancer.
  • Advanced strategic evaluation for omidubicel commercialization, including assessing whether to commercialize omidubicel ourselves or to pursue strategic alternatives to commercialize omidubicel, upon receipt of regulatory approval. The company currently has sufficient cash to fund the company’s operations into mid-2023, excluding the cost of commercializing omidubicel.

“2022 is a potentially transformative year for Gamida Cell as we continue to execute against our clinical and regulatory milestones. We were excited that the FDA accepted our BLA submission with priority review, and if approved, omidubicel will be the first allogeneic advanced stem cell therapy donor source for patients with blood cancers in need of a stem cell transplant. We believe that omidubicel has the potential to change the outlook for patients suffering from blood cancers through improved outcomes, quality of life and increased access for patients who are currently eligible for transplant, but cannot find a match,” said Julian Adams, Ph.D., chief executive officer of Gamida Cell. “In addition, the development of our NAM-enabled NK cell therapy candidate, GDA-201, creates an opportunity to potentially bring a new treatment option to tens of thousands of patients with relapsed/refractory lymphoma worldwide. We continue to execute our mission of advancing our broad pipeline of NAM-enabled cell therapies with a curative approach for patients with solid tumors and blood cancers and other serious blood diseases.”

Second Quarter and Recent Developments

Omidubicel: Advanced Cell Therapy

  • BLA accepted by FDA with Priority Review: In August 2022, the FDA accepted for filing Gamida Cell’s BLA for omidubicel for the treatment of patients with blood cancers in need of an allogeneic hematopoietic stem cell transplant. The FDA granted Priority Review for the BLA and has set a PDUFA target action date of January 30, 2023. In parallel, Gamida Cell is preparing for the commercialization of omidubicel in the U.S.

GDA-201: NAM-Enabled NK Cell Therapy

  • Dosed the first patient in Phase 1/2 study of cryopreserved formulation of GDA-201: In August 2022, Gamida Cell completed the dosing of the first patient in a company-sponsored Phase 1/2 study evaluating a cryopreserved formulation of GDA-201 for the treatment of follicular and diffuse B-cell lymphomas.

    • The Phase 1 portion of the study is designed as a dose escalation phase to evaluate the safety of GDA-201, and will include patients with follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL)/high grade B-cell lymphoma (HGBCL), marginal zone lymphoma or mantle cell lymphoma. The Phase 2 expansion phase is designed to evaluate the safety and efficacy of GDA-201 in 63 patients comprised of two patient cohorts, FL and DLBCL. The study will include patients who have relapsed or refractory lymphoma after at least two prior treatments, which may include CAR-T or stem cell transplant.

NAM-Enabled NK Cell Pipeline Expansion

  • Progressed NAM-enabled genetically modified NK pipeline: Gamida Cell continues to progress its NAM-enabled genetically modified NK pipeline, which utilizes CAR, membrane bound- and CRISPR-mediated technologies to increase targeting, potency and persistence against hematologic malignancies and solid tumors. The company continues to conduct in vitro and in vivo preclinical proof-of-concept studies for these genetically modified NK therapeutic targets which are already showing encouraging results and plans to select the next NK pipeline product candidate for IND enabling studies by the end of 2022. These therapeutic targets include:

    • GDA-301: Knockout of CISH (cytokine inducible SH2 containing protein) in NK cells using CRISPR/Cas9 in combination with a membrane-bound IL-15/IL-15Ra;
    • GDA-401: A development candidate with an undisclosed target;
    • GDA-501: Anti HER2 CAR-engineered NK cells to target solid tumors expressing HER2, based on a single-chain variable fragment of the widely used humanized monoclonal antibody trastuzumab; and
    • GDA-601: CRISPR Knockout of CD38 on NK cells combined with anti CD38 CAR. CD38 is an established immunotherapeutic target in multiple myeloma, but its expression on NK cells and its further induction during ex vivo NK cell expansion represents a barrier to the development of an anti CD38 CAR-NK cell therapy. Gamida Cell is advancing this program in collaboration with the Dana-Farber Cancer Institute to study the in vitro cytotoxicity of GDA-601 in fresh tumor tissue samples from multiple myeloma patients.

Corporate Updates

  • Appointed Ivan M. Borrello, M.D. to Board of Directors: Dr. Borrello is an Associate Professor of Oncology at the Sydney Kimmel Comprehensive Cancer Center at Johns Hopkins and a renowned physician and author who has made major contributions to better the understanding of immunotherapies and the treatment of hematologic malignancies as well as bone marrow transplant. The Company also announced the resignation of Ofer Gonen from its Board of Directors.

Second Quarter 2022 Financial Results

  • Research and development expenses were $10.6 million in the second quarter of 2022, compared to $13.4 million in the same quarter in 2021. The decrease was attributable mainly to a $2.4 million decrease in clinical activities relating to the conclusion of our Phase 3 clinical trial and a decrease of $0.4 million in the GDA-201 clinical program.
  • Commercial expenses were $3.2 million in the second quarter of 2022, compared to $5.0 million in the second quarter of 2021. The decrease was attributable mainly to reducing near-term commercial readiness expenses, as we continued to assess strategic approaches for the commercialization of omidubicel.
  • General and administrative expenses were $4.3 million in the second quarter of 2022, compared to $3.9 million in the same period in 2021. The increase was mainly due to a $0.9 million increase in professional services expenses, offset by a decrease of $0.5 million in headcount related expenses.
  • Finance expenses, net, were $0.5 million in the second quarter of 2022, compared to $1.3 million in the same period in 2021. The decrease was primarily due to $0.6 million in non-cash expenses and an increase of $0.2 million in interest income from cash management.
  • Net loss was $18.6 million in the second quarter of 2022, compared to a net loss of $23.6 million in the second quarter of 2021.

2022 Financial Guidance

Gamida Cell expects that its current cash, cash equivalents and investments will support the company’s ongoing operating activities into mid 2023, excluding the cost of commercializing omidubicel. If we decide to market omidubicel ourselves, we will require substantial additional funding. This cash runaway guidance is based on the company’s current operational plans and excludes any additional funding and any business development activities that may be undertaken. Gamida Cell continues to assess all financing options that support its corporate strategy.

Expected Milestones in 2022 and Early 2023

Omidubicel

  • PDUFA target action date of January 30, 2023.

NK cell pipeline expansion

  • Conduct preclinical proof of concept studies of the NAM-enabled, genetically modified NK therapeutic targets
  • Select pipeline candidate for IND-enabling studies

Conference Call Information

Gamida Cell will host a conference call today, August 15, 2022, at 8:00 a.m. ET to discuss these financial results and company updates. To access the conference call, please register here and be advised to do so at least 10 minutes prior to joining the call. A live webcast of the conference call can be accessed in the “Investors & Media” section of Gamida Cell’s website at www.gamida-cell.com. A replay of the webcast will be available approximately two hours after the event, for approximately 30 days.

About Omidubicel

Omidubicel is an advanced cell therapy candidate developed as a potential life-saving allogeneic hematopoietic stem cell (bone marrow) transplant for patients with blood cancers. Omidubicel demonstrated a statistically significant reduction in time to neutrophil engraftment in comparison to standard umbilical cord blood in an international, multi-center, randomized Phase 3 study (NCT0273029) in patients with hematologic malignancies undergoing allogeneic bone marrow transplant. The Phase 3 study also showed reduced time to platelet engraftment, reduced infections and fewer days of hospitalization. One-year post-transplant data showed sustained clinical benefits with omidubicel as demonstrated by significant reduction in infectious complications as well as reduced non-relapse mortality and no significant increase in relapse rates nor increases in graft-versus-host-disease (GvHD) rates. Omidubicel is the first stem cell transplant donor source to receive Breakthrough Therapy Designation from the FDA and has also received Orphan Drug Designation in the US and EU.

Omidubicel is an investigational stem cell therapy candidate, and its safety and efficacy have not been established by the FDA or any other health authority. For more information about omidubicel, please visit https://www.gamida-cell.com.

About GDA-201

Gamida Cell applied the capabilities of its nicotinamide (NAM)-enabled cell expansion technology to develop GDA-201, an innate NK cell immunotherapy candidate for the potential treatment of hematologic and solid tumors in combination with standard of care antibody therapies. GDA-201, the lead candidate in the NAM-enabled NK cell pipeline, has demonstrated promising initial clinical study data. Preclinical studies have shown that GDA-201 may address key limitations of NK cells by increasing the cytotoxicity and in vivo retention and proliferation in the bone marrow and lymphoid organs. Furthermore, these data suggest GDA-201 may improve antibody-dependent cellular cytotoxicity (ADCC) and tumor targeting of NK cells. There are approximately 40,000 patients with relapsed/refractory lymphoma in the US and EU, which is the patient population that will be studied in the currently ongoing GDA-201 Phase 1/2 clinical trial.

For more information about GDA-201, please visit https://www.gamida-cell.com. For more information on the Phase 1/2 clinical trial of GDA-201, please visit www.clinicaltrials.gov.

GDA-201 is an investigational cell therapy candidate, and its safety and efficacy have not been established by the FDA or any other health authority.

About NAM Technology

Our NAM-enabling technology, supported by positive omidubicel Phase 3 results, is designed to enhance the number and functionality of targeted cells, enabling us to pursue a curative approach that moves beyond what is possible with existing therapies. Leveraging the unique properties of NAM (nicotinamide), we can expand and metabolically modulate multiple cell types — including stem cells and natural killer cells — with appropriate growth factors to maintain the cells’ active phenotype and enhance potency. Additionally, our NAM technology improves the metabolic fitness of cells, allowing for continued activity throughout the expansion process.

About Gamida Cell

Gamida Cell is pioneering a diverse immunotherapy pipeline of potentially curative cell therapy candidates for patients with solid tumor and blood cancers and other serious blood diseases. We apply a proprietary expansion platform leveraging the properties of NAM to allogeneic cell sources including umbilical cord blood-derived cells and NK cells to create therapy candidates with potential to redefine standards of care. These include omidubicel, an investigational product with potential as a life-saving alternative for patients in need of bone marrow transplant, and a line of modified and unmodified NAM-enabled NK cells targeted at solid tumor and hematological malignancies. For additional information, please visit www.gamida-cell.com or follow Gamida Cell on LinkedIn, Twitter, Facebook or Instagram at @GamidaCellTx.

Cautionary Note Regarding Forward Looking Statements

This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including with respect to timing of initiation and progress of, and data reported from, pre-clinical and clinical trials of Gamida Cell’s product candidates (including omidubicel and GDA-201), anticipated regulatory filings (including the timing of review of the BLA for omidubicel by the FDA), commercialization planning efforts, the potentially life-saving or curative therapeutic and commercial potential of Gamida Cell’s product candidates (including GDA-201 and omidubicel), Gamida Cell’s expectations for the clinical development milestones set forth herein, and Gamida Cell’s expectations regarding its projected cash, cash equivalents and investments to be used for operating activities. Any statement describing Gamida Cell’s goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to a number of risks, uncertainties and assumptions, including those related to: the impact that the COVID-19 pandemic could have on our business, including the scope, progress and expansion of Gamida Cell’s clinical trials and ramifications for the cost thereof; clinical, scientific, regulatory and technical developments; the process of developing and commercializing product candidates that are safe and effective for use as human therapeutics; and the endeavor of building a business around such product candidates. In light of these risks and uncertainties, and other risks and uncertainties that are described in the Risk Factors section and other sections of Gamida Cell’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission (SEC) on May 12, 2022, and other filings that Gamida Cell makes with the SEC from time to time (which are available at http://www.sec.gov), the events and circumstances discussed in such forward-looking statements may not occur, and Gamida Cell’s actual results could differ materially and adversely from those anticipated or implied thereby. Although Gamida Cell’s forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Gamida Cell. As a result, you are cautioned not to rely on these forward-looking statements.

 

 

CONDENSED CONSOLIDATED BALANCE SHEETS

U.S. dollars in thousands (except share and per share data)

 

 

 

June 30,

 

 

December 31,

 

 

 

2022

 

 

2021

 

ASSETS

 

 

 

 

 

 

 

 

 

 

 

 

 

CURRENT ASSETS:

 

 

 

 

 

 

Cash and cash equivalents

 

$

37,890

 

 

$

55,892

 

Marketable securities

 

 

17,172

 

 

 

40,034

 

Prepaid expenses and other current assets

 

 

2,294

 

 

 

2,688

 

 

 

 

 

 

 

 

 

 

Total current assets

 

 

57,356

 

 

 

98,614

 

 

 

 

 

 

 

 

 

 

NON-CURRENT ASSETS:

 

 

 

 

 

 

 

 

Restricted deposits

 

 

3,591

 

 

 

3,961

 

Property, plant and equipment, net

 

 

37,967

 

 

 

35,180

 

Operating lease right-of-use assets

 

 

6,107

 

 

 

7,236

 

Severance pay fund

 

 

1,579

 

 

 

2,148

 

Other long-term assets

 

 

1,421

 

 

 

1,647

 

 

 

 

 

 

 

 

 

 

Total non-current assets

 

 

50,665

 

 

 

50,172

 

 

 

 

 

 

 

 

 

 

Total assets

 

$

108,021

 

 

$

148,786

 

 

 

LIABILITIES AND EQUITY

 

 

 

 

 

 

 

 

 

 

 

 

 

CURRENT LIABILITIES:

 

 

 

 

 

 

Trade payables

 

$

2,738

 

 

$

8,272

 

Employees and payroll accruals

 

 

4,978

 

 

 

4,957

 

Operating lease liabilities

 

 

2,517

 

 

 

2,699

 

Accrued interest of convertible senior notes

 

 

1,652

 

 

 

1,640

 

Accrued expenses and other current liabilities

 

 

10,412

 

 

 

7,865

 

 

 

 

 

 

 

 

 

 

Total current liabilities

 

 

22,297

 

 

 

25,433

 

 

 

 

 

 

 

 

 

 

NON-CURRENT LIABILITIES:

 

 

 

 

 

 

 

 

Convertible senior notes, net

 

 

71,801

 

 

 

71,417

 

Accrued severance pay

 

 

1,840

 

 

 

2,396

 

Long-term operating lease liabilities

 

 

4,233

 

 

 

5,603

 

 

 

 

 

 

 

 

 

 

Total non-current liabilities

 

 

77,874

 

 

 

79,416

 

 

 

 

 

 

 

 

 

 

CONTINGENT LIABILITIES AND COMMITMENTS

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SHAREHOLDERS’ EQUITY:

 

 

 

 

 

 

 

 

Share capital –

 

 

169

 

 

 

169

 

Additional paid-in capital

 

 

383,915

 

 

 

381,225

 

Accumulated deficit

 

 

(376,234

)

 

 

(337,457

)

 

 

 

 

 

 

 

 

 

Total shareholders’ equity

 

 

7,850

 

 

 

43,937

 

 

 

 

 

 

 

 

 

Total liabilities and shareholders’ equity

 

$

108,021

 

 

$

148,786

 

 
 
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

U.S. dollars in thousands (except share and per share data)

 

 

 

Three months ended

June 30,

 

 

Six months ended

June 30,

 

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

 

 

Unaudited

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Research and development expenses, net

 

$

10,563

 

 

$

13,350

 

 

$

21,868

 

 

$

24,710

 

Commercial expenses

 

 

3,193

 

 

 

4,988

 

 

 

7,072

 

 

 

9,219

 

General and administrative expenses

 

 

4,290

 

 

 

3,874

 

 

 

8,429

 

 

 

7,387

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total operating loss

 

 

18,046

 

 

 

22,212

 

 

 

37,369

 

 

 

41,316

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Financial expenses, net

 

 

508

 

 

 

1,345

 

 

 

1,408

 

 

 

1,427

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss

 

$

18,554

 

 

$

23,557

 

 

$

38,777

 

 

$

42,743

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss per share, basic and diluted

 

 

0.31

 

 

 

0.40

 

 

 

0.65

 

 

 

0.72

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average number of shares

 

 

59,546,273

 

 

 

59,253,315

 

 

 

59,510,918

 

 

 

59,188,504

 

 
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

U.S. dollars in thousands (except share and per share data)

  

 

 

Six months ended

June 30,

 

 

 

 

2022

 

 

2021

 

Cash flows from operating activities:

 

 

 

 

 

 

 

Loss

 

 

$

(38,777

)

 

$

(42,743

)

Adjustments to reconcile loss to net cash used in operating activities:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Depreciation of property, plant and equipment

 

 

 

224

 

 

 

206

 

Financing expense (income), net

 

 

 

(273

)

 

 

1,694

 

Share-based compensation

 

 

 

2,530

 

 

 

2,025

 

Amortization of issuance costs

 

 

 

385

 

 

 

269

 

Operating lease right-of-use assets

 

 

 

1,226

 

 

 

1,032

 

Operating lease liabilities

 

 

 

(1,649

)

 

 

(1,187

)

Accrued severance pay, net

 

 

 

14

 

 

 

 

Increase in prepaid expenses and other assets

 

 

 

(19

)

 

 

(358

)

Decrease in trade payables

 

 

 

(5,535

)

 

 

(884

)

Increase (decrease) in accrued expenses and current liabilities

 

 

 

2,285

 

 

 

(622

)

 

 

 

 

 

 

 

 

 

 

Net cash used in operating activities

 

 

 

(39,589

)

 

 

(40,568

)

 

 

 

 

 

 

 

 

 

 

Cash flows from investing activities:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Purchase of property, plant and equipment

 

 

 

(1,540

)

 

 

(6,118

)

Purchase of marketable securities

 

 

 

(3,708

)

 

 

(68,151

)

Proceeds from maturity of marketable securities

 

 

 

26,175

 

 

 

17,824

 

Proceeds (investments) from restricted deposits

 

 

 

500

 

 

 

(1,000

)

 

 

 

 

 

 

 

 

 

 

Net cash provided by (used in) investing activities

 

 

$

21,427

 

 

$

(57,445

)

  

 

 

 

 

 

 

 

Cash flows from financing activities:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Proceeds from exercise of options

 

 

$

76

 

 

$

556

 

Proceeds from share issuance, net

 

 

 

84

 

 

 

 

Proceeds from issuance of convertible senior notes, net

 

 

 

 

 

 

70,777

 

 

 

 

 

 

 

 

 

 

 

Net cash provided by financing activities

 

 

 

160

 

 

 

71,333

 

 

 

 

 

 

 

 

 

 

 

Decrease in cash and cash equivalents

 

 

 

(18,002

)

 

 

(26,680

)

Cash and cash equivalents at beginning of period

 

 

 

55,892

 

 

 

127,170

 

 

 

 

 

 

 

 

 

 

 

Cash and cash equivalents at end of period

 

 

$

37,890

 

 

$

100,490

 

 

 

 

 

 

 

 

 

 

 

Significant non-cash transactions:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Purchase of property, plant and equipment on credit

 

 

 

282

 

 

 

1,563

 

 

 

 

 

 

 

 

 

 

 

Supplemental disclosures of cash flow information:

 

 

 

 

 

 

 

 

 

Cash paid for interest

 

 

$

(2,203

)

 

$

 

 

  

Contacts

For investors:
Courtney Turiano

Stern Investor Relations, Inc.

Courtney.Turiano@sternir.com
1-212-362-1200

For media:
Heather DiVecchia

Chief of Staff

Heather@gamida-cell.com
1-617-892-9083